Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3217608 | 0.77 | PDE4B (0.39) | PDE4B | |
| SCHEMBL3220951 | 0.74 | PDE4B (0.38) | PDE4B | |
| SCHEMBL3221861 | 0.74 | PDE4B (0.41) | PTGS2PDE4B | |
| SCHEMBL3217935 | 0.74 | PDE4B (0.45) | PDE4B | |
| SCHEMBL13240788 | 0.66 | TGFBR1 (0.36) | PTGS1PTGS2PDE4BTGFBR1 | |
| SCHEMBL1465848 | 0.66 | — | — | |
| SCHEMBL2965146 | 0.64 | BACE1 (0.33) | PDE4BTGFBR1 | |
| SCHEMBL2959742 | 0.64 | PTGS2 (0.36) | PTGS2PDE4BTGFBR1 | |
| SCHEMBL4610096 | 0.62 | IDO1 (0.35) | — | |
| SCHEMBL6701853 | 0.62 | ALDH1A1 (0.32) | PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056791-A1 | Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20090318385-A1 | Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2060572-A1 | PYRAZOLOPYRIDINE DERIVATIVE AND PHOSPHODIESTERASE (PDE) INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2009-05-20 | — | — | EP | disclosed |
| EP-2058310-A1 | PYRAZOLOPYRIDINE CARBOXAMIDE DERIVATIVE AND PHOSPHODIESTERASE (PDE) INHIBITOR COMPRISING THE DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318385-A1 | Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient | PDE3A, PDE5A, PDE3B | ALOX5 3556/4885PTGS1 515/4885PTGS2 980/4885 |
| US-20100056791-A1 | Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same | PDE5A, PDE3A, PDE2A | ALOX5 1602/4885PTGS1 282/4885PTGS2 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.